Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
ATH-1020 by Athira Pharma for Neuropathic Pain (Neuralgia): Likelihood of Approval
ATH-1020 is under clinical development by Athira Pharma and currently in Phase I for Neuropathic Pain (Neuralgia). According to GlobalData,...
ATH-1020 by Athira Pharma for Anxiety Disorders: Likelihood of Approval
ATH-1020 is under clinical development by Athira Pharma and currently in Phase I for Anxiety Disorders. According to GlobalData, Phase...
ATH-1020 by Athira Pharma for Depression: Likelihood of Approval
ATH-1020 is under clinical development by Athira Pharma and currently in Phase I for Depression. According to GlobalData, Phase I...
ATH-1020 by Athira Pharma for Schizophrenia: Likelihood of Approval
ATH-1020 is under clinical development by Athira Pharma and currently in Phase I for Schizophrenia. According to GlobalData, Phase I...
ATH-1020 by Athira Pharma for Neurodegenerative Diseases: Likelihood of Approval
ATH-1020 is under clinical development by Athira Pharma and currently in Phase I for Neurodegenerative Diseases. According to GlobalData, Phase...